OTC · Healthcare

Evofem Biosciences, Inc. (EVFM)

As-reported financials and recent SEC filings for Evofem Biosciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$20.2M

Net income

$391,000

Net margin

1.9%

Diluted EPS

$0.00

ROE

-0.5%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$20.2M	$19.4M	$18.2M	$16.8M	$8.2M
Gross profit	$15.6M	$15.5M	$11.7M	$12.4M	$4.2M
Operating income	$3.4M	$-7.7M	$-17.8M	$-84.1M	$-166.8M
Net income	$391,000	$-8.9M	$53.0M	$-76.7M	$-205.2M
Diluted EPS	$0.00	$-0.00	$0.01	$-0.01	$-0.03

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-05-18

10-Q2026-05-15

8-K2026-04-30

8-K2026-04-16

8-K2026-03-19

8-K2026-03-11

10-K2026-03-11

8-K2026-01-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on EVFM

Search Evofem Biosciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.